thalidomide has been researched along with alvocidib in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Byun, JS; De Luca, P; De Siervi, A; Figg, WD; Gardner, K; Ge, Y; Gueron, G; Haggerty, CM; Li, QQ; Quintero, J; Sadiq-Ali, SG; Yabe, IM | 1 |
| Blum, KA; Byrd, JC; Dalton, JT; Farley, KL; Grever, MR; Hofmeister, CC; Johnson, AJ; Liu, Q; Muthusamy, N; Phelps, MA; Schaaf, LJ | 1 |
| Lin, TS | 2 |
| Ohmachi, K | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Adusumilli, M; Andritsos, LA; Blum, KA; Byrd, JC; Cardone, MH; Doykin, C; Flynn, J; Grever, MR; Jiang, Y; Johnson, AJ; Jones, JA; Maddocks, K; Phelps, MA; Pierceall, WE; Rozewski, D; Wei, L; Zhao, Y | 1 |
| Cotignola, J; De Luca, P; De Siervi, A; Elguero, B; Figg, WD; Gardner, K; Meiss, R; Spallanzani, RG; Vallecorsa, P; Vazquez, E; Zalazar, F | 1 |
4 review(s) available for thalidomide and alvocidib
| Article | Year |
|---|---|
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Flavonoids; Humans; Indoles; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maximum Tolerated Dose; Nitrogen Mustard Compounds; Piperidines; Pyrroles; Thalidomide; Thionucleotides; Treatment Outcome | 2008 |
New agents in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; Flavonoids; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thalidomide | 2010 |
[Present status and perspective of targeted therapy for B-cell lymphoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Drug Discovery; Flavonoids; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lenalidomide; Lymphoma, B-Cell; Molecular Targeted Therapy; Piperidines; Protease Inhibitors; Protein Kinase C; Protein Kinase C beta; Protein-Tyrosine Kinases; Pyrazines; Rituximab; Thalidomide; Vorinostat | 2011 |
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
2 trial(s) available for thalidomide and alvocidib
| Article | Year |
|---|---|
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; Spectrometry, Mass, Electrospray Ionization; Thalidomide; Time Factors | 2008 |
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Middle Aged; Piperidines; Recurrence; Thalidomide; Treatment Outcome; Tumor Lysis Syndrome | 2015 |
4 other study(ies) available for thalidomide and alvocidib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combinatorial antileukemic disruption of oxidative homeostasis and mitochondrial stability by the redox reactive thalidomide 2-(2,4-difluoro-phenyl)-4,5,6,7-tetrafluoro-1H-isoindole-1,3(2H)-dione (CPS49) and flavopiridol.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Free Radical Scavengers; Glutathione; Homeostasis; Humans; Intracellular Space; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; NF-kappa B; Nuclear Proteins; Organ Specificity; Oxidation-Reduction; Piperidines; Proto-Oncogene Proteins; Reactive Oxygen Species; Thalidomide; Transcription, Genetic; Tumor Suppressor Proteins | 2008 |
Low doses of CPS49 and flavopiridol combination as potential treatment for advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Flavonoids; Humans; Male; Mice; Mice, Nude; Piperidines; Prostatic Neoplasms; Thalidomide; Treatment Outcome | 2015 |